ArticleNature reviews. Clinical oncology2022
Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood.
Abstract readPublished Erratum
In one paragraph
Article in Nature reviews. Clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- When tumors speak: Understanding EEG periodic discharges in primary brain tumors and their clinical relevance.Neuro-oncology practice · 2026Article
- Extent of resection and perioperative neurological status as prognostic markers in glioblastoma: a population-based study.Journal of neuro-oncology · 2026Article
- Cerebrospinal fluid cfDNA-based molecular assessment of resection extent and prognosis in glioma.Communications medicine · 2026Article
- Neuro-Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets.MedComm · 2026Review
- Engineering a modular FAP-targeting ferritin-based drug nanocarrier for enhanced glioblastoma theranostics.Theranostics · 2026Article
- Combined inhibition by PRMT5 and MAT2A demonstrates a strong synthetic lethality in MTAP homozygous-deficient glioma models.Cell death discovery · 2025Article
- Radiotherapy-induced Hypothalamic-Pituitary axis dysfunction in adult Brain, head and neck and skull base tumor patients - A systematic review and Meta-Analysis.Clinical and translational radiation oncology · 2025Review
- Article
- Genomic Profiling in Glioma Patients to Explore Clinically Relevant Markers.International journal of molecular sciences · 2024Article
- Mitogen-activated protein kinase kinase kinase 1 facilitates the temozolomide resistance and migration of GBM via the MEK/ERK signalling.Journal of cellular and molecular medicine · 2024Article
- Lessons from Post-Immunotherapy Tumor Tissues in Clinical Trials: How Can We Fuel the Tumor Microenvironment in Gliomas?Vaccines · 2024Review
- Looking through the imaging perspective: the importance of imaging necrosis in glioma diagnosis and prognostic prediction - single centre experience.Radiology and oncology · 2024Article
- Prognosis and clinical features analysis of EMT-related signature and tumor Immune microenvironment in glioma.Journal of medical biochemistry · 2023Article
- Cancer vaccine strategies for the treatment of diffusely infiltrating gliomas.Therapeutic advances in vaccines and immunotherapy · 2023Review
- Radiomics for pseudoprogression prediction in high grade gliomas: added value of MR contrast agent.Heliyon · 2022Article
- Assessment of the Validity of Carbon Ion Irradiation for C6 Gliomas in Rats.Dose-response : a publication of International Hormesis SocietyArticle
- Circulating tumor DNA as a liquid biopsy for glioma detection in cerebrospinal fluid and plasma: A systematic review and meta-analysis.Neuro-oncology advancesReview
- Advancements in noninvasive visualization of the immune environment in glioblastoma: A systematic review.Neuro-oncology advancesArticle
Corrections and comments
- Erratum for
Authors and funding
24 authors.
Michael WellerDepartment of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland. michael.weller@usz.ch.
Martin van den BentBrain Tumor Center at Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands.ORCID http://orcid.org/0000-0001-5710-5127
Matthias PreusserDivision of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0003-3541-2315
Emilie Le RhunDepartment of Neurosurgery, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
Jörg C TonnDepartment of Neurosurgery, University Hospital Munich LMU, Munich, Germany.
Giuseppe MinnitiRadiation Oncology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.ORCID http://orcid.org/0000-0003-1239-1603
Martin BendszusDepartment of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany.
Carmen BalanaCatalan Institute of Oncology (ICO), Hospital Germans Trias i Pujol, Badalona, Spain.ORCID http://orcid.org/0000-0003-0771-0390
Olivier ChinotAix-Marseille Université, Assistance Publique-Hôpitaux de Marseille (APHM), CHU Timone, Department of Neuro-Oncology, Marseille, France.
Linda DirvenDepartment of Neurology, Leiden University Medical Center, Leiden, Netherlands.
Pim FrenchDepartment of Neurology, Erasmus MC, Rotterdam, Netherlands.ORCID http://orcid.org/0000-0002-0668-9529
Monika E HegiDepartment of Clinical Neurosciences, University Hospital Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0003-0855-6495
Asgeir S JakolaDepartment of Neurosurgery, Sahlgrenska University Hospital, Gothenburg, Sweden.ORCID http://orcid.org/0000-0002-2860-9331
Michael PlattenDepartment of Neurology, Medical Faculty Mannheim, Mannheim Center for Translational Neuroscience (MCTN), Heidelberg University, Mannheim, Germany.
Patrick RothDepartment of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
Roberta RudàDepartment of Neuro-Oncology, University Hospital, Turin, Italy.
Susan ShortLeeds Institute of Medical Research, St James's University Hospital, Leeds, UK.ORCID http://orcid.org/0000-0003-4423-7256
Marion SmitsDepartment of Radiology and Nuclear Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.ORCID http://orcid.org/0000-0001-5563-2871
Martin J B TaphoornDepartment of Neurology, Leiden University Medical Center, Leiden, Netherlands.
Andreas von DeimlingDepartment for Neuropathology, University Hospital Heidelberg, Heidelberg, Germany.
Manfred WestphalDepartment of Neurosurgery, University Hospital Hamburg, Hamburg, Germany.
Riccardo SoffiettiDepartment of Neuro-Oncology, University Hospital, Turin, Italy.ORCID http://orcid.org/0000-0002-9204-7038
Guido ReifenbergerDepartment of Neuropathology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Wolfgang WickNeurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-6171-634X
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.